HHS to Cut 10,000 Jobs, Downsize Key Health Agencies
The Department of Health and Human Services (HHS) will eliminate 10,000 full-time jobs, marking one of the largest federal health workforce reductions in decades. Major agencies—including the CDC, FDA, NIH, and CMS—will see significant downsizing. HHS will consolidate 28 divisions into 15 under a new umbrella agency, the Administration for Healthy America (AHA), absorbing SAMHSA and HRSA. This move will affect HIV treatment, mental health services, and healthcare access.
The CDC will lose 2,400 employees, impacting global health, HIV prevention, and injury prevention programs, including gun violence research. The FDA will cut 3,500 jobs, raising concerns over delays in drug and device approvals. NIH will shed 1,200 positions, potentially slowing research. CMS will reduce its staff by 300, though HHS says Medicare and Medicaid operations will remain intact.
Key Takeaway for Health Systems: Prepare for regulatory delays in drug and device approvals, potential cuts to public health funding, and disruptions in research and community health programs.
Trump Administration Rolls Back $11.4 Billion in COVID-19 Funds
The Trump administration will cut $11.4 billion in federal COVID-19 relief, halting support for vaccine distribution, testing, and public health research. Funding cuts to CDC programs will impact disease surveillance, lab testing, and vaccination. State health departments in California, Texas, and New York report immediate shortfalls, leading to staffing cuts and reduced outbreak monitoring. The administration argues pandemic-era funding is no longer necessary, but public health officials warn the rollback weakens U.S. readiness for emerging threats like drug-resistant TB and new flu strains.
Key Takeaway for Health Systems: Assess options to sustain infectious disease surveillance, vaccination, and emergency preparedness through state or private sector partnerships.
Dr. Marty Makary Confirmed as FDA Commissioner
Dr. Marty Makary was confirmed as FDA Commissioner in a 56–44 Senate vote on March 25, 2025. A Johns Hopkins surgeon and public health expert, Makary has criticized bureaucratic inefficiencies and has pledged to review mass layoffs at the FDA, prioritize opioid response, and emphasize safety in drug and device approvals. He may also revisit vaccine policies, given his past opposition to mandates.
Key Takeaway for Health Systems: Monitor potential shifts in FDA approval processes, vaccine policy, and opioid strategies. Expect alignment with the Trump administration’s “Make America Healthy Again” agenda, with implications for clinical operations and pharma partnerships.
DOJ Investigates UC System for Affirmative Action Violations
The Department of Justice has opened a compliance review into admissions practices at Stanford, UC Berkeley, UCLA, and UC Irvine. The inquiry examines whether race-conscious policies continue under DEI frameworks, potentially violating the Supreme Court’s affirmative action ruling. Institutions could face federal funding penalties or admissions restrictions if found noncompliant.
Key Takeaway for Health Systems: Medical schools and teaching hospitals should reassess DEI hiring and admissions practices for legal exposure, especially if federal scrutiny expands beyond academia.
Dr. Susan Monarez Nominated as CDC Director
President Trump has nominated Dr. Susan Monarez, currently acting CDC director, to lead the agency permanently. If confirmed, she would be the first non-physician CDC director in over 50 years and the first to undergo Senate confirmation under a 2022 law. Monarez brings experience from ARPA-H, DHS, and the White House Office of Science and Technology Policy. She is expected to advance innovation and public health infrastructure in partnership with HHS Secretary Robert F. Kennedy Jr.
Key Takeaway for Health Systems: Watch for policy shifts under Monarez’s leadership, particularly in biosecurity, pandemic preparedness, and chronic disease management. Changes to CDC funding or guidelines may affect clinical operations and strategy.
On The Horizon:
Federal Health Policy Overhaul Continues
As part of the ongoing federal restructuring, HHS agencies must submit consolidation plans by April 14, including strategies to cut overhead and relocate to lower-cost areas. Congress is also considering reductions to Medicaid, NIH research funding, and SNAP benefits, which could significantly impact hospitals, public health programs, and medical research.
Two key Supreme Court cases are also pending:
- Kennedy v. Braidwood Management (April 21): Challenges the ACA requirement for insurers to cover preventive services, potentially affecting access to screenings that save over 100,000 lives annually.
- Medina v. Planned Parenthood South Atlantic (next week): Will determine if states can block Medicaid funding to Planned Parenthood, with broad implications for reproductive health access.
Key Takeaway for Health Systems: Prepare for funding shifts, especially for research and Medicaid services. Monitor legal outcomes that could reshape preventive care and reproductive health access. The ongoing federal reorganization may impact hospital operations, grants, and strategic planning.